Work

Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy

Year: 2024

Type: article

Abstract: Chronic myeloid leukemia (CML) is a triphasic myeloproliferative disorder that accounts for 15–20% of adult leukemias [ 1 ]. The cytogenetic hallmark is a reciprocal translocation between chromosomes 9 and 22, resulting in BCR::ABL1 fusion gene. Lymphoid blast crisis (LBC) is one of the most dreaded complications of CML, with the B-cell lineage being more common [ 2 ]. Although the incidence of CML-LBC has decreased markedly in the tyrosine kinase inhibitor (TKI) era, responses to TKIs in CML-LBC are infrequent and of short-lived [ 3 ]. Chimeric antigen receptor T (CAR T) is an effective therapy for refractory/relapsed (R/R) B acute lymphoblastic leukemia (ALL) patients [ 4 , 5 , 6 ], but the therapeutic response and long-term prognosis of CML-LBC patients are unclear. We retrospectively collected the clinical data from 13 CML-LBC patients who received CAR T treatment at our center from February 2017 to March 2023 and compared their outcomes with those of 121 Philadelphia chromosome-positive (Ph + ) ALL patients who underwent CAR T treatment at our center during the same period (Figs. S2B and S3A ). All patients were diagnosed and differentially diagnosed by past medical history, morphology, immunology, cytogenetics and molecular biology. This study was approved by the Institutional Review Board of our hospital.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-024-01020-y